Siplizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Identifiers | |
| CAS Number | |
Siplizumab (MEDI-507) is a novel MAb with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |